絞り込み

16555

広告

駿府城跡から豊臣秀吉が築かせた石垣跡 一般公開 (NHK)

徳川家康が築いた静岡市にある駿府城の天守台跡付近から、当時、ライバル関係にあった豊臣秀吉が築かせた石垣跡が見つかり、20日、一般公開されました。 静岡市によりま...

  1. ケニアの政府プロジェクトにブロックチェー...
  2. 再生医療、規制強化へ がん免疫療法の臨床...
  3. 4メートル超の大わらじ 浅草寺奉納へ出発...
  4. J-Startupをはじめとするベンチャ...

ニュース一覧

The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration.

著者 Foley JE , Ahrén B
Eur Endocrinol.2017 Aug ; 13(2):56-61.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (74view , 0users)

Full Text Sources

The discovery of the incretin hormone glucagon like peptide-1 (GLP-1), and its usefulness in the treatment of type 2 diabetes mellitus (T2DM) followed by the finding that dipeptidyl peptidase-4 (DPP-4) inhibition prevents GLP-1 inactivation, led to the discovery of DPP-728. In 1999, studies with DPP-728 established the first proof-of-concept that DPP-4 inhibition improves glycaemic control in patients with T2DM. Further efforts to improve the binding kinetics of DPP-728 resulted in the discovery of vildagliptin (LAF237). In the last 20 years, a plethora of studies conducted by Novartis in collaboration with external investigators has demonstrated the mechanism of action of vildagliptin and its efficacy as monotherapy and as an add-on therapy for patients with T2DM. The studies establish that vildagliptin is a selective DPP-4 inhibitor that blocks GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) inactivation, thereby prolonging their action, resulting in improved glycaemic control. This review aims to discuss the discovery and development of vildagliptin, with an emphasis on mechanism of action and clinical efficacy.
PMID: 29632608 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード